Unione Europea - italiano - EMA (European Medicines Agency)

eli lilly nederland b.v. - necitumumab - carcinoma, polmone non a piccole cellule - agenti antineoplastici - portrazza in combinazione con chemioterapia gemcitabina e cisplatino è indicato per il trattamento di pazienti adulti con recettore localmente avanzato o metastatico fattore di crescita epidermico (egfr) esprimendo il cancro del polmone non a piccole cellule squamose che non hanno ha ricevuto la chemioterapia preventiva per questa condizione.

Unione Europea - italiano - EMA (European Medicines Agency)

nektar therapeutics uk limited - etirinotecan pegol - neoplasie al seno - agenti antineoplastici - il trattamento di cancro al seno con metastasi al cervello.

Unione Europea - italiano - EMA (European Medicines Agency)

xbiotech germany gmbh - anticorpo monoclonale umano igg1 specifico per l'interleuchina-1 alfa umana - neoplasie colorettali - agenti antineoplastici - trattamento del cancro colorettale metastatico.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

seagen international gmbh - tucatinibum - compresse rivestite con film - tucatinibum 50 mg, copovidonum, crospovidonum, natrii chloridum, kalii chloridum, natrii hydrogenocarbonas, silica colloidalis anhydrica, cellulosum microcristallinum, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 4000, talcum, e 172 (flavum), pro compresso obducto corresp. natrium 9.21 mg, kalium 10.10 mg. - zur behandlung von metastasiertem her2-positivem brustkrebs - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

seagen international gmbh - tucatinibum - compresse rivestite con film - tucatinibum 150 mg, copovidonum, crospovidonum, natrii chloridum, kalii chloridum, natrii hydrogenocarbonas, silica colloidalis anhydrica, cellulosum microcristallinum, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 4000, talcum, e 172 (flavum), pro compresso obducto corresp. natrium 27.65 mg, kalium 30.29 mg. - zur behandlung von metastasiertem her2-positivem brustkrebs - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - agenti antineoplastici - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Unione Europea - italiano - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - tumori stromali gastrointestinali - agenti antineoplastici - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Unione Europea - italiano - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - agenti antineoplastici - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Unione Europea - italiano - EMA (European Medicines Agency)

immunocore ireland limited - tebentafusp - uveal neoplasms - agenti antineoplastici - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Unione Europea - italiano - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostatica neoplasie, castrazione-resistente - agenti antineoplastici - treatment of adult patients with prostate cancer.